ROIV logo

ROIV Roivant Sciences Ltd.

NASDAQ Global Market · Biotechnology · Healthcare

$38.73
+0.02 (+0.05%)

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions …

Market Cap: $28.06Broivant.com

Price

$36.34+27.37%
$27.83$30.82$33.82$36.81
Apr 30Aug 7

Social Signal Score

57
5d
70
1 mentions
+0.0%
30d
55
4 mentions
+0.0%
60d
56
7 mentions
+0.0%
90d
47
24 mentions
+0.0%
news: 24

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 2Sell 0Strong Sell 0
Avg price target$49.5+27.8%
Low $41Median $49High $62
Current Consensus

Revenue

$35.12M+105.96%
$1.44M$12.67M$23.89M$35.12M
Dec 2022Sep 2026

Analyst Estimates

FY2026
$-1.12
$-1.74–$-0.51
4 analysts
FY2027
$-1.15
$-1.78–$-0.52
4 analysts
FY2028
$-1.14
$-1.76–$-0.51
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Matthew Gline
Sector
Healthcare
Industry
Biotechnology
Employees
721
Beta
1.20
Country
GB
Piotroski score
2 / 9 (Weak)
Altman Z-score
44.74
roivant.com